Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Product prescribing issue? 948 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 948 reports of Product prescribing issue have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.3% of all adverse event reports for LENALIDOMIDE.

948
Reports of Product prescribing issue with LENALIDOMIDE
0.3%
of all LENALIDOMIDE reports
4
Deaths
42
Hospitalizations

How Dangerous Is Product prescribing issue From LENALIDOMIDE?

Of the 948 reports, 4 (0.4%) resulted in death, 42 (4.4%) required hospitalization, and 1 (0.1%) were considered life-threatening.

Is Product prescribing issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 948 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Product prescribing issue?

DUPILUMAB (1,715) POLYETHYLENE GLYCOL 3350 (1,439) OXYCODONE (646) RIVAROXABAN (359) ACETAMINOPHEN\OXYCODONE (347) ETONOGESTREL (311) ACETAMINOPHEN\HYDROCODONE (298) CERTOLIZUMAB PEGOL (297) CABOZANTINIB S-MALATE (294) MORPHINE (288)

Which LENALIDOMIDE Alternatives Have Lower Product prescribing issue Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Product prescribing issue Reports All Drugs Causing Product prescribing issue LENALIDOMIDE Demographics